Booming CRISPR pioneer Intellia looks to double staff with new digs
Making way for some ambitious growth plans that include doubling its current work force to some 200 staffers, CRISPR/Cas9 player Intellia Therapeutics threw a party to cut the ribbon on its new research digs.
Intellia grabbed new lab space at 40 Erie Street in Cambridge, MA, boosting its space from 15,000 to 80,000 square feet. And its keeping its facility at 130 Brookline Street.
Intellia scored a $108 million IPO back in May, as investors bought in $NTLA to the sizzling hot field of gene editing. But its $18 price at the time has damped down, and the stock is currently trading at $15.53.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
